A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Bio N Tech Se stock. As of the latest transaction made, Bridgewater Associates, LP holds 5,673 shares of BNTX stock, worth $641,786. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,673
Holding current value
$641,786
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$78.36 - $124.66 $444,536 - $707,196
5,673 New
5,673 $673,000
Q4 2023

Feb 14, 2024

BUY
$90.91 - $112.75 $371,185 - $460,358
4,083 New
4,083 $430,000
Q2 2022

Aug 11, 2022

BUY
$123.25 - $186.24 $1.5 Million - $2.26 Million
12,156 New
12,156 $1.81 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.5B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.